StockDriftsStockDriftsTop 34 Lion Point Capital LP Holdings
| Stock | Company | % Port. | Shares | Value | Activity | Ownership | Avg. Cost | Date |
|---|---|---|---|---|---|---|---|---|
| PRAX | PRAXIS PRECISION MEDICINES I | 7.13% | 4.5K | $1.5M | +0.00%(+0) | $47.52(+671.83%) | 2026-06-30 | |
| MLTX | MOONLAKE IMMUNOTHERAPEUTICS | 6.29% | 67.5K | $1.3M | +0.00%(+0) | $27.19(-39.19%) | 2026-06-30 | |
| FENC | FENNEC PHARMACEUTICALS INC | 5.78% | 112.4K | $1.2M | +0.00%(+0) | $8.73(+34.31%) | 2026-06-30 | |
| RPRX | ROYALTY PHARMA PLC | 5.74% | 21.4K | $1.2M | +0.00%(+0) | $35.65(+66.04%) | 2026-06-30 | |
| CMPS | COMPASS PATHWAYS PLC | 5.41% | 80.0K | $1.1M | +0.00%(+0) | $4.80(+180.14%) | 2026-06-30 | |
| MIST | MILESTONE PHARMACEUTICALS IN | 5.26% | 820.0K | $1.1M | +0.00%(+0) | $2.65(-58.52%) | 2026-06-30 | |
| BNTC | BENITEC BIOPHARMA INC | 3.97% | 62.0K | $830K | +0.00%(+0) | $9.14(+37.48%) | 2026-06-30 | |
| SNDX | SYNDAX PHARMACEUTICALS INC | 3.76% | 36.0K | $787K | +0.00%(+0) | $20.82(-4.70%) | 2026-06-30 | |
| BHVN | BIOHAVEN LTD | 3.68% | 51.7K | $769K | +0.00%(+0) | $25.97(-43.62%) | 2026-06-30 | |
| GERN | GERON CORP | 3.54% | 578.0K | $740K | +0.00%(+0) | $2.57(-42.70%) | 2026-06-30 |
| Performance Metric | 3-Year Annualized | 3-Year Cumulative | 5-Year Annualized | 5-Year Cumulative |
|---|---|---|---|---|
| Top 20 Holdings Weighted | +8.34% | +27.15% | -4.53% | -20.67% |
| Top 20 Holdings Unweighted | +8.92% | +29.20% | -0.43% | -2.13% |
Lion Point Capital LP reports $20.91M in US-listed equity holdings across 35 positions in its most recent 13F filing. Its largest disclosed positions are PRAX (7.1%), MLTX (6.3%) and FENC (5.8%). The top 20 holdings account for 75.77% of reported assets. Its disclosed equity book has returned +27.15% on a three-year cumulative basis. Figures reflect the Q2 2026 filing.
Sign up free to track Lion Point Capital LP, compare funds side by side, and get alerts the moment positions change.
Holdings on this page are parsed from Lion Point Capital LP’s Form 13F filings with the U.S. Securities and Exchange Commission (CIK 1643354). View Lion Point Capital LP’s 13F filings on SEC